How long should pindolol be associated with paroxetine to improve the antidepressant response?

被引:152
作者
Zanardi, R [1 ]
Artigas, F [1 ]
Franchini, L [1 ]
Sforzini, L [1 ]
Gasperini, M [1 ]
Smeraldi, E [1 ]
Perez, J [1 ]
机构
[1] CSIC,INST INVEST BIOMED,DEPT NEUROCHEM,BARCELONA,SPAIN
关键词
D O I
10.1097/00004714-199712000-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A double-blind study was undertaken to investigate the period of treatment with the beta-adrenoreceptor/5-hydroxytryptamine 1A (5-HT1A) antagonist pindolol required to enhance the antidepressant effects of paroxetine. After 1 meek of a placebo run-in period, 63 untreated major depressive inpatients mere randomly assigned to three different groups. Group 1 received paroxetine (20 mg/day) plus placebo (4 weeks). Group 2 received paroxetine (20 mg/day) plus pindolol (7.5 mg/day) for 1 meek and placebo for 3 weeks. Group 3 received both active treatments for the entire duration of the study (4 weeks). Clinical response was defined as a reduction of the score in the Hamilton Rating Scale for Depression (HAM-D) to 8 or below. Also, to preliminarily examine whether beta-adrenoreceptor blockade was involved in the action of pindolol, another group of 10 inpatients was treated in an open-label manner with paroxetine (20 mg/day) plus 50 mg/day of the beta-adrenergic antagonist metoprolol, devoid of significant affinity for 5-HT1A receptors. At-endpoint, the incidence of treatment-emergent side effects did not significantly differ among the three groups. After 1 and 2 weeks of treatment, the two groups treated with paroxetine plus pindolol displayed a significantly greater response rate than the group treated with paroxetine plus placebo. At study completion, only the patients treated with pindolol for the entire period showed a significantly greater response rate (p = 0.05). HAM-D scores mere also significantly lower at endpoint in patients treated with the combination for 4 weeks (p = 0.00003). The group of patients treated with paroxetine and metoprolol exhibited a side-effect profile comparable to that of paroxetine alone. Response rates mere also comparable. These findings support the efficacy of pindolol, but not of metoprolol, in accelerating the antidepressant effect of paroxetine and suggest that the administration of pindolol for the entire period of the acute treatment may increase the efficacy of paroxetine.
引用
收藏
页码:446 / 450
页数:5
相关论文
共 19 条
[1]   THE EFFICACY OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN DEPRESSION - A METAANALYSIS OF STUDIES AGAINST TRICYCLIC ANTIDEPRESSANTS [J].
ANDERSON, IM ;
TOMENSON, BM .
JOURNAL OF PSYCHOPHARMACOLOGY, 1994, 8 (04) :238-249
[2]   The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram [J].
Arborelius, L ;
Nomikos, GG ;
Hertel, P ;
Salmi, P ;
Grillner, P ;
Hook, BB ;
Hacksell, U ;
Svensson, TH .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 353 (06) :630-640
[3]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[4]  
ARTIGAS F, 1995, ARCH GEN PSYCHIAT, V52, P969
[5]  
ARTIGAS F, 1994, ARCH GEN PSYCHIAT, V51, P248
[6]   5-HT AND ANTIDEPRESSANTS - NEW VIEWS FROM MICRODIALYSIS STUDIES [J].
ARTIGAS, F .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (07) :262-262
[7]   INCREASED ANTIDEPRESSANT USE IN PATIENTS PRESCRIBED BETA-BLOCKERS [J].
AVORN, J ;
EVERITT, DE ;
WEISS, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 255 (03) :357-360
[8]  
Berman RM, 1997, AM J PSYCHIAT, V154, P37
[9]   CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION [J].
BLIER, P ;
DEMONTIGNY, C .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :220-226
[10]   EFFECTIVENESS OF PINDOLOL WITH SELECTED ANTIDEPRESSANT DRUGS IN THE TREATMENT OF MAJOR DEPRESSION [J].
BLIER, P ;
BERGERON, R .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (03) :217-222